Review





Similar Products

cb 5339  (MedChemExpress)
94
MedChemExpress cb 5339
Cb 5339, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb 5339/product/MedChemExpress
Average 94 stars, based on 1 article reviews
cb 5339 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
length derlin  (MedChemExpress)
94
MedChemExpress length derlin
Length Derlin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/length derlin/product/MedChemExpress
Average 94 stars, based on 1 article reviews
length derlin - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
cb-5339  (Alturas Analytics Inc)
90
Alturas Analytics Inc cb-5339
Clinical trial schema for the comparative study of <t>CB-5339</t> in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.
Cb 5339, supplied by Alturas Analytics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb-5339/product/Alturas Analytics Inc
Average 90 stars, based on 1 article reviews
cb-5339 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Clinical trial schema for the comparative study of CB-5339 in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.

Journal: Molecular cancer therapeutics

Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

doi: 10.1158/1535-7163.MCT-22-0167

Figure Lengend Snippet: Clinical trial schema for the comparative study of CB-5339 in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.

Article Snippet: An HPLC/MS/MS method was developed at Alturas Analytics, Inc. to determine concentrations of CB-5339 in dog K 2 EDTA plasma in accordance with internal Standardized Operating Procedures.

Techniques:

Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the Powder in Capsule formulation of CB-5339.

Journal: Molecular cancer therapeutics

Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

doi: 10.1158/1535-7163.MCT-22-0167

Figure Lengend Snippet: Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the Powder in Capsule formulation of CB-5339.

Article Snippet: An HPLC/MS/MS method was developed at Alturas Analytics, Inc. to determine concentrations of CB-5339 in dog K 2 EDTA plasma in accordance with internal Standardized Operating Procedures.

Techniques: Formulation

Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the human clinical formulation of CB-5339.

Journal: Molecular cancer therapeutics

Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

doi: 10.1158/1535-7163.MCT-22-0167

Figure Lengend Snippet: Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the human clinical formulation of CB-5339.

Article Snippet: An HPLC/MS/MS method was developed at Alturas Analytics, Inc. to determine concentrations of CB-5339 in dog K 2 EDTA plasma in accordance with internal Standardized Operating Procedures.

Techniques: Formulation

Comparison of timecourse samples representative of induction of pharmacodynamic markers K48 linkage-specific ubiquitin (A) and CHOP (B, by mRNA) in serial biopsy samples taken from 6 dogs receiving the human clinical formulation of CB-5339.

Journal: Molecular cancer therapeutics

Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

doi: 10.1158/1535-7163.MCT-22-0167

Figure Lengend Snippet: Comparison of timecourse samples representative of induction of pharmacodynamic markers K48 linkage-specific ubiquitin (A) and CHOP (B, by mRNA) in serial biopsy samples taken from 6 dogs receiving the human clinical formulation of CB-5339.

Article Snippet: An HPLC/MS/MS method was developed at Alturas Analytics, Inc. to determine concentrations of CB-5339 in dog K 2 EDTA plasma in accordance with internal Standardized Operating Procedures.

Techniques: Comparison, Formulation